Dreva'l A V, Gite'l E P, Dreva'l T P
Lab Delo. 1989(10):41-7.
The kinetics of 131I-labeled intravenous insulin was examined in 13 patients with diabetes mellitus and in 2 nondiabetics, and the kinetics of unlabeled intravenous insulin ('insulrap') was followed up in 7 patients with insulin-dependent diabetes. Antibodies to exogenous insulin were titered in examinees' blood sera. The kinetic curves of labeled and unlabeled insulin were processed with the use of a two-compartmental model, thus obtaining compatible kinetics parameters. This permits the use of routine insulin dosage forms in pharmacokinetic studies, followed by the blood serum insulin radioimmunoassay. Antibodies to exogenous insulin increase the level of insulin dissemination, slow down its elimination from the blood (mostly in the beta-phase) and the total insulin clearance, with the antibody titer rise being parallelled by an acceleration+ of insulin dissemination and by deceleration of its elimination from the blood; besides, the fraction of antibodies, by fixing which insulin is slowly metabolized, increases.
对13例糖尿病患者和2例非糖尿病患者检测了131I标记的静脉注射胰岛素的动力学，并对7例胰岛素依赖型糖尿病患者随访了未标记的静脉注射胰岛素（“胰岛素放射配体分析法”）的动力学。检测受试者血清中外源性胰岛素抗体的滴度。使用二室模型处理标记和未标记胰岛素的动力学曲线，从而获得相符的动力学参数。这使得在药代动力学研究中能够使用常规胰岛素剂型，随后进行血清胰岛素放射免疫测定。外源性胰岛素抗体增加胰岛素的弥散水平，减缓其从血液中的清除（主要在β期）以及总胰岛素清除率，抗体滴度升高与胰岛素弥散加速和从血液中清除减速同时出现；此外，通过固定使胰岛素缓慢代谢的抗体比例增加。
